FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310109036> ?p ?o ?g. }

• W4310109036 endingPage "1513" @default.
• W4310109036 startingPage "1512" @default.
• W4310109036 abstract "Background: Systemic mastocytosis (SM) is a rare disease characterized by the proliferation of mast cells (MC). In about 95% of adult patients, SM is driven by a gain-of-function mutation (D816V) in exon 17 of the KIT gene. Advanced SM (AdvSM) is an aggressive, life-threatening form of SM and includes three subtypes; aggressive SM (ASM), SM with an associated hematologic neoplasm (SM-AHN), and MC leukemia (MCL). Bezuclastinib is an oral, highly selective, and potent tyrosine kinase inhibitor (TKI) with specificity for mutations in KIT exons 9, 11, 17, and 18, including D816V, while sparing closely related kinases (e.g., PDGFRα, PDGFRβ, and CSF1R). Results from a phase 1/2 study in patients with advanced solid tumors coupled with preclinical data have led to the on-going evaluation of bezuclastinib in patients with AdvSM, the Apex study (NCT04996875). The primary objective of this study is to evaluate the safety, efficacy, pharmacokinetic (PK), and pharmacodynamic (PD) profile of bezuclastinib in all AdvSM subtypes. Methods: Apex is a Phase 2, open-label, 2-part, multicenter study in adult patients with AdvSM per WHO diagnostic criteria, who have measurable SM-related organ damage according to modified IWG-MRT-ECNM consensus eligibility and response criteria (mIWG), and have a baseline serum tryptase of ≥20 ng/mL. Patients with a history of prior TKI therapy (e.g., avapritinib, midostaurin) are permitted in the study. In Part 1, patients are randomized 1:1:1:1 to bezuclastinib 50, 100, or 200 mg BID, or 400 mg QD. Data from Part 1 will inform dose selection for Part 2. The primary efficacy endpoint for this study is overall response rate (complete response [CR], CR with incomplete hematologic recovery [CRh], partial response [PR] and clinical improvement [CI]) as assessed by a Central Response Review Committee and based on mIWG response criteria. Results: As of May 24, 2022, 11 mIWG evaluable patients with AdvSM (ASM: n=2, SM-AHN: n=8, and MCL: n=1) were randomized in Part 1 to 50mg BID (n=3), 100mg BID (n=3), 200mg BID (n=3), and 400mg QD (n=2). The majority of patients were male (82%) and treatment naïve (82%) with ECOG PS 0-1 (82%) and positive for KIT D816V (91%). Median (range) BM MC burden and serum tryptase at baseline were 30% (7-80%) and 182 ng/mL (68-1578 ng/mL), respectively. Bezuclastinib was well-tolerated across all dose levels. Treatment Emergent Adverse Events (TEAEs) reported in >1 patient included anemia (n=3), neutropenia (n=2), and thrombocytopenia (n=2), a majority of which were low-grade. One serious AE of hypersensitivity (mediator flare) was reported. Two patients had an AE-related dose reduction with one patient subsequently re-escalating to the randomized dose. Preliminary clinical activity data showed that all 11 patients experienced a >50% reduction in serum tryptase from baseline, 10/11 (91%) within the first week of treatment; 6 (55%) patients achieved a serum tryptase level <20 ng/mL, 4/6 within the first cycle of treatment. Among patients with available data after ≥2 cycles of treatment, all 8 achieved a median reduction of 68% in KIT D816V variant allele fraction (VAF) and ≥50% reduction in BM MC, with 6/8 (75%) achieving complete clearance of MC aggregates. There were no reported instances of cognitive effects or intracranial bleeding. Conclusion: Early data suggest that bezuclastinib is well-tolerated and is associated with encouraging early signs of clinical activity as demonstrated by meaningful reductions in serum tryptase, MC burden, and KIT D816V VAF. Enrollment is currently ongoing. Updated safety and clinical activity as well as initial clinical objective response data will be presented." @default.
• W4310109036 created "2022-11-30" @default.
• W4310109036 creator A5013173470 @default.
• W4310109036 creator A5015788207 @default.
• W4310109036 creator A5017506171 @default.
• W4310109036 creator A5024492683 @default.
• W4310109036 creator A5028207893 @default.
• W4310109036 creator A5035984897 @default.
• W4310109036 creator A5042130426 @default.
• W4310109036 creator A5052086909 @default.
• W4310109036 creator A5065547046 @default.
• W4310109036 creator A5071407391 @default.
• W4310109036 creator A5080997283 @default.
• W4310109036 creator A5082924494 @default.
• W4310109036 creator A5088674908 @default.
• W4310109036 creator A5091087783 @default.
• W4310109036 date "2022-11-15" @default.
• W4310109036 modified "2023-10-13" @default.
• W4310109036 title "Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent <i>KIT</i> D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)" @default.
• W4310109036 doi "https://doi.org/10.1182/blood-2022-156311" @default.
• W4310109036 hasPublicationYear "2022" @default.
• W4310109036 type Work @default.
• W4310109036 citedByCount "5" @default.
• W4310109036 countsByYear W43101090362023 @default.
• W4310109036 crossrefType "journal-article" @default.
• W4310109036 hasAuthorship W4310109036A5013173470 @default.
• W4310109036 hasAuthorship W4310109036A5015788207 @default.
• W4310109036 hasAuthorship W4310109036A5017506171 @default.
• W4310109036 hasAuthorship W4310109036A5024492683 @default.
• W4310109036 hasAuthorship W4310109036A5028207893 @default.
• W4310109036 hasAuthorship W4310109036A5035984897 @default.
• W4310109036 hasAuthorship W4310109036A5042130426 @default.
• W4310109036 hasAuthorship W4310109036A5052086909 @default.
• W4310109036 hasAuthorship W4310109036A5065547046 @default.
• W4310109036 hasAuthorship W4310109036A5071407391 @default.
• W4310109036 hasAuthorship W4310109036A5080997283 @default.
• W4310109036 hasAuthorship W4310109036A5082924494 @default.
• W4310109036 hasAuthorship W4310109036A5088674908 @default.
• W4310109036 hasAuthorship W4310109036A5091087783 @default.
• W4310109036 hasBestOaLocation W43101090361 @default.
• W4310109036 hasConcept C121608353 @default.
• W4310109036 hasConcept C126322002 @default.
• W4310109036 hasConcept C170493617 @default.
• W4310109036 hasConcept C2778820342 @default.
• W4310109036 hasConcept C2780007613 @default.
• W4310109036 hasConcept C2780581156 @default.
• W4310109036 hasConcept C29730261 @default.
• W4310109036 hasConcept C31760486 @default.
• W4310109036 hasConcept C42362537 @default.
• W4310109036 hasConcept C71924100 @default.
• W4310109036 hasConcept C98274493 @default.
• W4310109036 hasConceptScore W4310109036C121608353 @default.
• W4310109036 hasConceptScore W4310109036C126322002 @default.
• W4310109036 hasConceptScore W4310109036C170493617 @default.
• W4310109036 hasConceptScore W4310109036C2778820342 @default.
• W4310109036 hasConceptScore W4310109036C2780007613 @default.
• W4310109036 hasConceptScore W4310109036C2780581156 @default.
• W4310109036 hasConceptScore W4310109036C29730261 @default.
• W4310109036 hasConceptScore W4310109036C31760486 @default.
• W4310109036 hasConceptScore W4310109036C42362537 @default.
• W4310109036 hasConceptScore W4310109036C71924100 @default.
• W4310109036 hasConceptScore W4310109036C98274493 @default.
• W4310109036 hasIssue "Supplement 1" @default.
• W4310109036 hasLocation W43101090361 @default.
• W4310109036 hasOpenAccess W4310109036 @default.
• W4310109036 hasPrimaryLocation W43101090361 @default.
• W4310109036 hasRelatedWork W1969154832 @default.
• W4310109036 hasRelatedWork W1982307539 @default.
• W4310109036 hasRelatedWork W2049447930 @default.
• W4310109036 hasRelatedWork W2075312788 @default.
• W4310109036 hasRelatedWork W2512058705 @default.
• W4310109036 hasRelatedWork W2908272576 @default.
• W4310109036 hasRelatedWork W2962775095 @default.
• W4310109036 hasRelatedWork W4310109036 @default.
• W4310109036 hasRelatedWork W4385899916 @default.
• W4310109036 hasRelatedWork W4386496024 @default.
• W4310109036 hasVolume "140" @default.
• W4310109036 isParatext "false" @default.
• W4310109036 isRetracted "false" @default.
• W4310109036 workType "article" @default.